Anavex Life Sciences Provides an Update on ANAVEX ®2-73 Rett Syndrome Program

NEW YORK– January 2, 2024 -- Anavex Life Sciences Corp. (“Anavex” or the“Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials